- Title: Subtitle
- PP01.106 Validation of Immunotherapy Response Score (IRS) for Predicting Pembrolizumab Monotherapy Benefit in First Line (1L) Non-small cell lung cancer (NSCLC)
- Creators
- Brandi Oakley - Strata Oncology, Ann Arbor, MI, USAJustin Moon - Kettering Health, Kettering, OH, USAMary Connolly - Kettering Health, Kettering, OH, USAMark E. Burkard - University of Wisconsin Carbone Cancer CenterJ. Marie Suga - Kaiser PermanenteSachdev Thomas - Kaiser PermanenteBenjamin J. Bulen - Strata Oncology, Ann Arbor, MI, USALaura E. Lamb - Strata Oncology, Ann Arbor, MI, USANickolay A. Khazanov - Strata Oncology, Ann Arbor, MI, USADan Hovelson - Strata Oncology, Ann Arbor, MI, USAHana Vakil - Strata Oncology, Ann Arbor, MI, USAAnna Dusenbery - Strata Oncology, Ann Arbor, MI, USAJonathan Mowers - Strata Oncology, Ann Arbor, MI, USAKat Kwiatkowski - Strata Oncology, Ann Arbor, MI, USAD. Bryan Johnson - Strata Oncology, Ann Arbor, MI, USADaniel R. Rhodes - Strata Oncology, Ann Arbor, MI, USAScott A. Tomlins - Strata Oncology, Ann Arbor, MI, USAMalek Safa - Kettering Health, Kettering, OH, USA
- Resource Type
- Abstract
- Publication Details
- Journal of thoracic oncology, Vol.19(7), pp.e47-e47
- DOI
- 10.1016/j.jtho.2024.05.333
- ISSN
- 1556-0864
- eISSN
- 1556-1380
- Publisher
- Elsevier Inc
- Language
- English
- Date published
- 07/2024
- Academic Unit
- Internal Medicine
- Record Identifier
- 9984700642702771
Abstract
PP01.106 Validation of Immunotherapy Response Score (IRS) for Predicting Pembrolizumab Monotherapy Benefit in First Line (1L) Non-small cell lung cancer (NSCLC)
Journal of thoracic oncology, Vol.19(7), pp.e47-e47
07/2024
DOI: 10.1016/j.jtho.2024.05.333
Details
Metrics
4 Record Views